These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas A, Hunt S, Bryla DA, Schneerson R, Robbins JB, Szu SC. Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232 [Abstract] [Full Text] [Related]
5. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R. N Engl J Med; 2002 Feb 14; 346(7):491-6. PubMed ID: 11844850 [Abstract] [Full Text] [Related]
6. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development. Salman M, St Michael F, Ali A, Jabbar A, Cairns C, Hayes AC, Rahman M, Iqbal M, Haque A, Cox AD. J Immunol Methods; 2017 Nov 14; 450():27-33. PubMed ID: 28735760 [Abstract] [Full Text] [Related]
7. Preclinical laboratory evaluation of a bivalent Staphylococcus aureus saccharide-exotoxin A protein conjugate vaccine. Ho MM, Bolgiano B, Martino A, Kairo SK, Corbel MJ. Hum Vaccin; 2006 Nov 14; 2(3):89-98. PubMed ID: 17012902 [Abstract] [Full Text] [Related]
8. Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Fattom A, Schneerson R, Szu SC, Vann WF, Shiloach J, Karakawa WW, Robbins JB. Infect Immun; 1990 Jul 14; 58(7):2367-74. PubMed ID: 2114365 [Abstract] [Full Text] [Related]
9. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Canh DG, Lin FY, Thiem VD, Trach DD, Trong ND, Mao ND, Hunt S, Schneerson R, Robbins JB, Chu C, Shiloach J, Bryla DA, Bonnet MC, Schulz D, Szu SC. Infect Immun; 2004 Nov 14; 72(11):6586-8. PubMed ID: 15501790 [Abstract] [Full Text] [Related]
11. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study. Fattom A, Matalon A, Buerkert J, Taylor K, Damaso S, Boutriau D. Hum Vaccin Immunother; 2015 Nov 14; 11(3):632-41. PubMed ID: 25483694 [Abstract] [Full Text] [Related]
12. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. Fattom A, Li X, Cho YH, Burns A, Hawwari A, Shepherd SE, Coughlin R, Winston S, Naso R. Vaccine; 1995 Oct 14; 13(14):1288-93. PubMed ID: 8585282 [Abstract] [Full Text] [Related]
13. Investigational vaccine for Escherichia coli O157: phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults. Konadu EY, Parke JC, Tran HT, Bryla DA, Robbins JB, Szu SC. J Infect Dis; 1998 Feb 14; 177(2):383-7. PubMed ID: 9466525 [Abstract] [Full Text] [Related]
15. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines. Thiem VD, Lin FY, Canh DG, Son NH, Anh DD, Mao ND, Chu C, Hunt SW, Robbins JB, Schneerson R, Szu SC. Clin Vaccine Immunol; 2011 May 14; 18(5):730-5. PubMed ID: 21411598 [Abstract] [Full Text] [Related]